Table 1 Baseline characteristics of patients treated sequentially with BRAF inhibitors and ipilimumab
Characteristic | BRAF inhibitor followed by ipilimumab (n = 28) | Ipilimumab followed by a BRAF inhibitor (n = 6) |
|---|---|---|
BRAF inhibitor, n (%) | ||
Vemurafenib | 12 (43) | 4 (67) |
Dabrafenib | 16 (57) | 2 (33) |
Median age, years | 50 | 48 |
Male/female, n (%) / n (%) | 18 (64) / 10 (36) | 4 (67) / 2 (33) |
ECOG PS | ||
0 | 15 (54) | 6 (100) |
1 | 13 (46) | 0 (0) |
LDH level, n (%) | ||
<1.10 ULN | 14 (50) | 3 (50) |
≥1.10 ULN | 14 (50) | 3 (50) |
Disease stage, n (%) | ||
Unresectable IIIc | 1 (4) | 0 (0) |
M1b | 2 (7) | 0 (0) |
M1c | 25 (89) | 6 (100) |
Brain metastasis, n (%) | 7 (25) | 3 (50) |
Previous therapy, n (%) | 14 (50) | 6 (100) |
Mage-A3 | 2 (7) | 1(17) |
Dacarbazine | 5 (18) | 1 (17) |
Temozolomide plus cisplatin | 2 (7) | 2 (33) |
Cisplatin, vinblastine and dacarbazine | 3 (11) | 0 (0) |
Fotemustine | 0 (0) | 1 (17) |
MEK inhibitor | 2 (7) | 1 (17) |